<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016674</url>
  </required_header>
  <id_info>
    <org_study_id>ALM-Lipo-VorFat-21-013</org_study_id>
    <nct_id>NCT05016674</nct_id>
  </id_info>
  <brief_title>Assessment of Cellular and Tissue Characteristics in Lipoaspirates Stirred by VorFat</brief_title>
  <official_title>Assessment of Cellular and Tissue Characteristics in Lipoaspirates Harvested With the LipoLife System and Stirred by VorFat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alma Lasers</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alma Lasers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, prospective, open-label study. The study aims to assess the structure and&#xD;
      viability of fat collected during the LipoLife liposuction procedure&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average adipose cell cluster size</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of adipose cell cluster size by microscope</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Laser Assisted Liposuction</condition>
  <arm_group>
    <arm_group_label>Laser-assisted liposuction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser-Assisted Liposuction with the LipoLife system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LipoLife system</intervention_name>
    <description>Abdominal Laser-Assisted Liposuction</description>
    <arm_group_label>Laser-assisted liposuction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects scheduled to undergo abdominal w/wo flanks laser-assisted liposuction surgery&#xD;
             and are willing to donate the harvested adipose tissue for the study assessment.&#xD;
&#xD;
          2. Between 18 and 70 years of age.&#xD;
&#xD;
          3. Estimated fat harvesting of at least 300 milliliters.&#xD;
&#xD;
          4. Provided written Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or intending to become pregnant during the course of study.&#xD;
&#xD;
          2. Current smoker.&#xD;
&#xD;
          3. Presence of known malignancy.&#xD;
&#xD;
          4. Active infection in the treatment area.&#xD;
&#xD;
          5. History of autoimmune disorder (e.g., Systemic Lupus Erythematosus [SLE]).&#xD;
&#xD;
          6. History of connective, metabolic, or atrophic skin disease.&#xD;
&#xD;
          7. History of keloid scarring.&#xD;
&#xD;
          8. Chronic use (&gt;7 consecutive days) of anticoagulants (such as aspirin) or NSAIDs within&#xD;
             15 days before enrollment.&#xD;
&#xD;
          9. Subjects with immune system diseases.&#xD;
&#xD;
         10. Any other reason that in the opinion of the investigator, prevents the subject from&#xD;
             participating in the study or compromises the subject safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Jason Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jason Martin, M.D.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Jason Martin, MD</last_name>
    <phone>(303) 321-1439</phone>
    <email>wjasonmartinmd@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Kilian</last_name>
    <phone>(303) 321-1439</phone>
    <email>amy@jasonmartinmd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>William Jason Martin, MD</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Kilian</last_name>
      <phone>303-321-1439</phone>
      <email>amy@jasonmartinmd.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

